Published in Nat Med on March 01, 2006
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
The cardiofaciocutaneous syndrome. J Med Genet (2006) 2.32
An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23
Protein tyrosine phosphatase function: the substrate perspective. Biochem J (2007) 2.17
Noonan syndrome. Orphanet J Rare Dis (2007) 2.10
Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci (2008) 1.84
Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab (2011) 1.82
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet (2006) 1.79
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst (2013) 1.78
Leopard syndrome. Orphanet J Rare Dis (2008) 1.69
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer (2008) 1.66
Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal (2009) 1.59
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54
MAP'ing CNS development and cognition: an ERKsome process. Neuron (2009) 1.49
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron (2007) 1.47
Specific functions for ERK/MAPK signaling during PNS development. Neuron (2011) 1.45
Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. Proc Natl Acad Sci U S A (2008) 1.40
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
DLC1: a significant GAP in the cancer genome. Genes Dev (2008) 1.36
Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol (2009) 1.36
Functional specificity of ras isoforms: so similar but so different. Genes Cancer (2011) 1.30
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A (2009) 1.25
Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. Eur J Hum Genet (2009) 1.22
ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell (2012) 1.18
Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes (2012) 1.18
Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries. Genes Dev (2010) 1.17
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
An unexpected new role of mutant Ras: perturbation of human embryonic development. J Mol Med (Berl) (2007) 1.11
Distinct functions for ERKs? J Biol (2006) 1.08
SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet (2007) 1.08
Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arterioscler Thromb Vasc Biol (2010) 1.05
Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet (2014) 1.04
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem (2008) 1.03
Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol Cell Biol (2010) 1.02
SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet (2009) 1.01
What's new in the neuro-cardio-facial-cutaneous syndromes? Eur J Pediatr (2007) 0.99
Legius syndrome in fourteen families. Hum Mutat (2011) 0.95
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. Proc Natl Acad Sci U S A (2009) 0.94
Globularity and language-readiness: generating new predictions by expanding the set of genes of interest. Front Psychol (2014) 0.94
SRF regulates craniofacial development through selective recruitment of MRTF cofactors by PDGF signaling. Dev Cell (2014) 0.92
RASSF1A: Not a prototypical Ras effector. Small GTPases (2011) 0.90
Transient Blockade of ERK Phosphorylation in the Critical Period Causes Autistic Phenotypes as an Adult in Mice. Sci Rep (2015) 0.90
The INT6 cancer gene and MEK signaling pathways converge during zebrafish development. PLoS One (2007) 0.90
The cullin7 E3 ubiquitin ligase: a novel player in growth control. Cell Cycle (2008) 0.90
FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. J Bone Miner Metab (2011) 0.90
Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol (2012) 0.87
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations. Mol Syst Biol (2014) 0.86
Receptor tyrosine kinases modulate distinct transcriptional programs by differential usage of intracellular pathways. Elife (2015) 0.83
LEOPARD Syndrome: Clinical Features and Gene Mutations. Mol Syndromol (2012) 0.82
The other side of Turner's: Noonan's syndrome. Indian J Endocrinol Metab (2013) 0.82
Genome-wide gene expression in a patient with 15q13.3 homozygous microdeletion syndrome. Eur J Hum Genet (2013) 0.80
Probiotic supplementation promotes calcification in Danio rerio larvae: a molecular study. PLoS One (2013) 0.80
MAPK signaling determines anxiety in the juvenile mouse brain but depression-like behavior in adults. PLoS One (2012) 0.79
Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway. PLoS One (2012) 0.78
Dentate Gyrus Development Requires ERK Activity to Maintain Progenitor Population and MAPK Pathway Feedback Regulation. J Neurosci (2015) 0.77
The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon. J Neurosci (2014) 0.76
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. J Am Acad Dermatol (2016) 0.75
Feedback activation of neurofibromin terminates growth factor-induced Ras activation. Cell Commun Signal (2016) 0.75
Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation. Bioorg Med Chem (2016) 0.75
Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities. Orphanet J Rare Dis (2016) 0.75
The impact of the genetic background in the Noonan syndrome phenotype induced by K-Ras(V14I). Rare Dis (2015) 0.75
Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy. JCI Insight (2017) 0.75
Warty skin changes, chronic scrotal lymphoedema, and facial dysmorphism. BMJ Case Rep (2010) 0.75
STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27
Mathematical models of protein kinase signal transduction. Mol Cell (2002) 4.08
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med (2006) 3.66
PTP1B regulates leptin signal transduction in vivo. Dev Cell (2002) 3.61
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science (2002) 3.12
The nanomechanical signature of breast cancer. Nat Nanotechnol (2012) 2.89
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell (2004) 2.82
The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev (2008) 2.74
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem (2005) 2.68
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
The "Gab" in signal transduction. Trends Cell Biol (2003) 2.52
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell (2012) 2.34
B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity (2007) 2.28
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem (2002) 2.17
A role for the scaffolding adapter GAB2 in breast cancer. Nat Med (2005) 2.12
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem (2008) 2.08
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest (2016) 2.06
Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol (2002) 2.03
The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev (2007) 1.97
FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity (2007) 1.90
Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes (2008) 1.88
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell (2006) 1.84
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A (2004) 1.82
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res (2007) 1.82
Direct identification of PTEN phosphorylation sites. FEBS Lett (2002) 1.80
Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice. Immunity (2013) 1.80
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood (2009) 1.79
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 1.68
Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci U S A (2013) 1.66
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer (2008) 1.66
Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol (2007) 1.66
Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med (2013) 1.64
Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem (2003) 1.59
The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell (2005) 1.58
Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol (2007) 1.56
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res (2011) 1.52
Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Res (2013) 1.49
Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. Blood (2013) 1.49
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer (2012) 1.49
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem (2002) 1.48
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron (2007) 1.47
Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol (2005) 1.41
In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res (2004) 1.40
Regulation of protein tyrosine phosphatase 1B by sumoylation. Nat Cell Biol (2006) 1.40
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood (2011) 1.36
Live-cell imaging of enzyme-substrate interaction reveals spatial regulation of PTP1B. Science (2007) 1.36
Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell (2011) 1.34
PTP-1B is an essential positive regulator of platelet integrin signaling. J Cell Biol (2005) 1.34
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature (2013) 1.33
Critical role for scaffolding adapter Gab2 in Fc gamma R-mediated phagocytosis. J Cell Biol (2003) 1.28
The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem (2006) 1.27
The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene (2002) 1.26
Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem (2004) 1.25
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A (2009) 1.25
Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep (2012) 1.24
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice. J Biol Chem (2005) 1.23
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell (2010) 1.22
Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab (2011) 1.21
SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. J Cell Physiol (2004) 1.21
Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation (2008) 1.20
Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol (2004) 1.20
TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev (2011) 1.18
Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. Diabetes (2004) 1.18
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One (2012) 1.16
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res (2010) 1.16
Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS One (2008) 1.15
Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress. Biochem J (2011) 1.14
A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood (2010) 1.14
PTP1B regulates Eph receptor function and trafficking. J Cell Biol (2010) 1.14
Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2. Biochemistry (2011) 1.13
Enhanced retinal insulin receptor-activated neuroprotective survival signal in mice lacking the protein-tyrosine phosphatase-1B gene. J Biol Chem (2010) 1.13
Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. Mol Cell Biol (2009) 1.12
SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase. J Cell Biol (2003) 1.12
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem (2007) 1.12
Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis. PLoS One (2012) 1.12
Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med (2002) 1.11
SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J Cell Biol (2006) 1.10
Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from FcepsilonRI. J Immunol (2006) 1.08
Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase. Mol Cell Biol (2004) 1.06
Phosphorylated alpha-actinin and protein-tyrosine phosphatase 1B coregulate the disassembly of the focal adhesion kinase x Src complex and promote cell migration. J Biol Chem (2005) 1.06
Wolfram Syndrome protein, Miner1, regulates sulphydryl redox status, the unfolded protein response, and Ca2+ homeostasis. EMBO Mol Med (2013) 1.04